Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Inclusion Criteria: * 1\) Prostate cancer confirmed by histology; * 2\) ≥ 18 years old; * 3\) The presence of metastatic lesions confirmed by bone scan and/or CT/MRI and/or PET-CT; * 4\) ECOG score 0-2; * 5\) Continuously maintain ADT treatment and maintain testosterone levels ≤ 50ng/dL; The progression of prostate cancer recorded within 6 months prior to screening; * 6\) Having received at least one NHT in the past before progressing; * 7\) HER2 IHC 1+, 2+, or 3+; * 8\) Inability to or refusal docetaxel chemotherapy; * 9\) Voluntarily join the study; * 10\) Expected survival time ≥ 6 months; * 11\) Normal function of main organs; Exclusion Criteria: * 1)Have a history of malignant tumors other than prostate cancer; * 2)Previously received allogeneic stem cell or parenchymal organ transplantation; * 3\) Previously or currently suffering from congenital or acquired immunodeficiency diseases; * 4\) The patient have a history of allergy to RC48 or paclitaxel, or a history of Hypersensitivity to chimeric or humanized antibodies or fusion proteins, or allergy to excipients of the study drug; * 5\) Other significant clinical and laboratory abnormalities that affect safety evaluation; * 6\) Those who are unwilling or unable to take effective contraceptive measures; * 7\) Subjects with active brain metastasis;